Study of OZURDEX® in the Treatment of Diabetic Macular Oedema (DME) in Australia - The AUSSIEDEX Study

NCT02731911 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 202

Last updated 2019-01-23

No results posted yet for this study

Summary

This prospective study will assess Ozurdex in the treatment of Diabetic Macular Oedema in clinical practice.

Conditions

  • Diabetic Macular Oedema

Interventions

DRUG

dexamethasone intravitreal implant

Ozurdex® treatment for diabetic macular oedema as per standard of care in clinical practice.

Sponsors & Collaborators

  • Allergan

    lead INDUSTRY

Principal Investigators

  • Dr. George Labib · Allergan

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2016-04-29
Primary Completion
2018-10-22
Completion
2018-10-22

Countries

  • Australia

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02731911 on ClinicalTrials.gov